Clinical characteristics and survival of japanese patients with connective tissue disease and pulmonary arterial hypertension: A single-centre cohort

Rheumatology (United Kingdom)

Volumn 51, Issue 10, 2012, Pages 1846-1854

  Shirai, Yuichiro ^a   Yasuoka, Hidekata ^a   Okano, Yutaka ^b   Takeuchi, Tsutomu ^a   Satoh, Toru ^c   Kuwana, Masataka ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KAWASAKI MUNICIPAL HOSPITAL   (Japan)

^c Division of Cardiology   (Japan)

Author keywords

Anti U1RNP antibody; Mixed connective tissue disease; Pulmonary arterial hypertension; Scleroderma; Systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; BERAPROST; BOSENTAN; CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PROSTACYCLIN; SILDENAFIL;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOPULMONARY HEMODYNAMICS; CARDIOVASCULAR RISK; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HUMAN; JAPANESE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIXED CONNECTIVE TISSUE DISEASE; MORTALITY; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; COHORT STUDIES; CONNECTIVE TISSUE DISEASES; EARLY DIAGNOSIS; FEMALE; HUMANS; HYPERTENSION, PULMONARY; JAPAN; MALE; MIDDLE AGED; PROGNOSIS; RISK; SURVIVAL RATE;

EID: 84867127141     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes140     Document Type: Article

References (36)

1. Koh ET, Lee P, Gladman DD et al. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996;35:989-93.
2. Trad S, Amoura Z, Beigelman C et al. Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum 2006;54:184-91.
3. Vegh J, Szodoray P, Kappelmayer J et al. Clinical and immunoserological characteristics of mixed connective tissue disease associated with pulmonary arterial hypertension. Scand J Immunol 2006;64:69-76.
4. Chung L, Liu J, Parsons L et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 2010;138:1383-94.
5. Condliffe R, Kiely DG, Peacock AJ et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009; 179:151-7.
6. Humbert M, Sitbon O, Chaouat A et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006;173:1023-30.
7. Ruiz-Cano MJ, Escribano P, Alonso R et al. Comparison of baseline characteristics and survival between patients with idiopathic and connective tissue disease-related pulmonary arterial hypertension. J Heart Lung Transplant 2009;28:621-7.
8. Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003;48: 516-22.
9. Mukerjee D, George D, Coleiro B et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003;62:1088-93.
10. Launay D, Humbert M, Berezne A et al. Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease. Chest 2011;140:1016-24.
11. Hesselstrand R, Wildt M, Ekmehag B, Wuttge DM, Scheja A. Survival in patients with pulmonary arterial hypertension associated with systemic sclerosis from a Swedish single centre: prognosis still poor and prediction difficult. Scand J Rheumatol 2011;40:127-32.
12. Mathai SC, Hummers LK, Champion HC et al. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum 2009;60:569-77.
13. Kasukawa R, Nishimaki T, Takagi T et al. Pulmonary hypertension in connective tissue disease. Clinical analysis of sixty patients in multi-institutional study. Clin Rheumatol 1990;9:56-62.
14. Williams MH, Das C, Handler CE et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 2006;92:926-32.
15. Hachulla E, Carpentier P, Gressin V et al. Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study. Rheumatology 2009;48:304-8.
16. Denton CP, Pope JE, Peter HH et al. Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann Rheum Dis 2008;67:1222-8.
17. Badesch DB, Champion HC, Sanchez MA et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009;30:S55-66.
18. Denton CP, Humbert M, Rubin L, Black CM. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 2006;65:1336-40.
19. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40: 1725.
20. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
21. Kasukawa R, Tojo T, Miyawaki S. Preliminary diagnostic criteria for classification of mixed connective tissue disease. In: Kasukawa R, Sharp GC, eds. Mixed connective tissue disease and antinuclear antibodies. Amsterdam: Elsevier, 1987:41-7.
22. Vitali C, Bombardieri S, Jonsson R et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
23. Kuwana M, Kaburaki J, Okano Y, Tojo T, Homma M. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 1994;37:75-83.
24. Campo A, Mathai SC, Le Pavec J et al. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med 2010; 182:252-60.
25. Smolen JS, Steiner G. Mixed connective tissue disease: to be or not to be? Arthritis Rheum 1998;41:768-77.
26. Medsger TA. Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being. Rheum Dis Clin North Am 2003;29:255-73.
27. Miyamichi-Yamamoto S, Fukumoto Y, Sugimura K et al. Intensive immunosuppressive therapy improves pulmonary hemodynamics and long-term prognosis in patients with pulmonary arterial hypertension associated with connective tissue disease. Circ J 2011;75:2668-74.
28. Chen CH, Chen HA, Wang HP et al. Pulmonary arterial hypertension in autoimmune diseases: an analysis of 19 cases from a medical center in northern Taiwan. J Microbiol Immunol Infect 2006;39:162-8.
29. Zhang R, Dai LZ, Xie WP et al. Survival of Chinese patients with pulmonary arterial hypertension in the modern management era. Chest 2011;140:301-9.
30. Kim WU, Min JK, Lee SH, Park SH, Cho CS, Kim HY. Causes of death in Korean patients with systemic lupus erythematosus: a single center retrospective study. Clin Exp Rheumatol 1999;17:539-45.
31. Lau EM, Manes A, Celermajer DS, Galie' N. Early detection of pulmonary vascular disease in pulmonary arterial hypertension: time to move forward. Eur Heart J 2011;32:2489-98.
32. Avouc J, Airo P, Meune C et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol 2010;37:2290-8.
33. Hachulla E, Gressin V, Guillevin L et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005;52:3792-800.
34. Sanchez O, Stibon O, Jais X, Simonneau G, Humbert M. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest 2006;130:182-9.
35. Kato M, Kataoka H, Odani T et al. The short-term role of corticosteroid therapy for pulmonary arterial hypertension associated with connective tissue diseases: report of five cases and a literature review. Lupus 2011;20: 1047-56.
36. Shapiro S, Traiger GL, Turner M, McGoon MD, Wason P, Barst RJ. Sex differences in the diagnosis, treatment, and outcome of patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term pulmonary arterial hypertension management. Chest 2012;141:363-73. 1854